Nicolas Boute
YOU?
Author Swipe
View article: 147P Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
147P Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020 Open
V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) is an immune checkpoint regulator that is highly expressed in myeloid cells in the tumor microenvironment (TME). VISTA has been shown to maintain immunosuppressive conditions …
View article: Data from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
Data from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors Open
The insulin-like growth factor type 1 receptor (IGF-1R) is important in tumorigenesis, and its overexpression occurs in numerous tumor tissues. To date, therapeutic approaches based on mAbs and tyrosine kinase inhibitors targeting IGF-1R h…
View article: Table S1, Table S2, Table S3, Table S4, Figure S1Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7 from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
Table S1, Table S2, Table S3, Table S4, Figure S1Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7 from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors Open
Table S1 shows expression of IGF1R on human tissues Table S2 shows expression of IGF1R on Tumor and Normal cells Table S3 shows DAR calculation Table S4 shows impact of W0101 on cell cycle Figure S1 shows the flowchart for selection of m20…
View article: Data from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
Data from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors Open
The insulin-like growth factor type 1 receptor (IGF-1R) is important in tumorigenesis, and its overexpression occurs in numerous tumor tissues. To date, therapeutic approaches based on mAbs and tyrosine kinase inhibitors targeting IGF-1R h…
View article: Table S1, Table S2, Table S3, Table S4, Figure S1Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7 from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
Table S1, Table S2, Table S3, Table S4, Figure S1Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7 from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors Open
Table S1 shows expression of IGF1R on human tissues Table S2 shows expression of IGF1R on Tumor and Normal cells Table S3 shows DAR calculation Table S4 shows impact of W0101 on cell cycle Figure S1 shows the flowchart for selection of m20…
View article: Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors Open
The insulin-like growth factor type 1 receptor (IGF-1R) is important in tumorigenesis, and its overexpression occurs in numerous tumor tissues. To date, therapeutic approaches based on mAbs and tyrosine kinase inhibitors targeting IGF-1R h…
View article: A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells
A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells Open
The type IV C-X-C-motif chemokine receptor (CXCR4) is expressed in a large variety of human cancers, including hematologic malignancies, and this receptor and its ligand, stromal cell–derived factor-1 (SDF-1), play a crucial role in cancer…
View article: A novel antagonist anti‐cMet antibody with antitumor activities targeting both ligand‐dependent and ligand‐independent c‐Met receptors
A novel antagonist anti‐cMet antibody with antitumor activities targeting both ligand‐dependent and ligand‐independent c‐Met receptors Open
c‐Met is a prototypic member of a sub‐family of RTKs. Inappropriate c‐Met activation plays a crucial role in tumor formation, proliferation and metastasis. Using a key c‐Met dimerization assay, a set of 12 murine whole IgG1 monoclonal anti…
View article: NanoLuc Luciferase – A Multifunctional Tool for High Throughput Antibody Screening
NanoLuc Luciferase – A Multifunctional Tool for High Throughput Antibody Screening Open
Based on the recent development of NanoLuc luciferase (Nluc), a small (19 kDa), highly stable, ATP independent, bioluminescent protein, an extremely robust and ultra high sensitivity screening system has been developed whereby primary hits…